Pulse Biosciences, Inc

AngioDynamics, Inc. specializes in the development, manufacturing, and commercialization of a diverse array of medical, surgical, and diagnostic instruments. These products are utilized by healthcare professionals to address conditions such as peripheral vascular disease, facilitate vascular access, and support various oncology and surgical interventions, serving both domestic and international markets. The company's portfolio includes advanced ablation systems like NanoKnife, designed for the precise surgical removal of soft tissues, and Solero microwave and radiofrequency systems, effective in ablating solid cancerous or benign growths. Additionally, they provide BioSentry tract sealant systems, IsoLoc Endorectal Balloons, Alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits. Their endovascular therapies segment encompasses solutions for thrombus management, atherectomy procedures, core peripheral products, and the treatment of venous insufficiency. Furthermore, AngioDynamics is a key supplier of vascular access devices, such as peripherally inserted central catheters (PICCs), midline catheters, implantable ports, and dialysis catheters, along with associated accessories. These are primarily employed for short-duration systemic drug delivery, including chemotherapy and antibiotics, marketed under a robust portfolio of brand names such as BioFlo, BioFlo Midline, BioFlo PICC, Xcela PICC, PASV, BioFlo Port, SmartPort, Vortex, LifeGuard, BioFlo DuraMax, and DuraMax. The company distributes its offerings directly to a specialized clientele, including interventional radiologists, cardiologists, vascular surgeons, urologists, interventional and surgical oncologists, and critical care nurses, while also leveraging established distributor networks. Founded in 1988, AngioDynamics maintains its corporate headquarters in Latham, New York.

Encision Inc. (ECIA), established in 1991 and headquartered in Boulder, Colorado, operates as a medical device firm specializing in the development, manufacturing, and commercialization of proprietary surgical instruments for the U.S. market. The company's core offering revolves around its patented Active Electrode Monitoring (AEM) technology, featured in both surgical instruments and dedicated monitors. This innovative system significantly enhances patient safety and optimizes outcomes during laparoscopic surgical procedures. Encision's AEM instrument portfolio encompasses a diverse array of endo-mechanical tools, such as scissors, graspers, and dissectors, alongside specialized fixed-tip and suction-irrigation electrodes. Beyond these, the company supplies specialized handles designed for complex laparoscopic operations, characterized by their robust shafts and ergonomic designs. They also provide the AEM EndoShield 2 burn protection systems. Complementing these instruments, Encision markets its AEM monitor product line, essential for use in conjunction with its AEM instruments. Distribution of Encision's products occurs through a hybrid sales model, leveraging both direct company representatives and an established network of independent sales agents.

RefleXion Medical, Inc.Medical TechnologyUnited States

69% matchPrivate

RefleXion Medical, Inc. is a Hayward, California-based medical technology company developing advanced biology-guided radiotherapy systems for cancer treatment.

Stimcell Energetics Inc.STME · BiotechVancouver, Canada

67% matchPublic

StimCell Energetics Inc. is a biotechnology company focused on the research, development, and market introduction of both therapeutic and non-therapeutic solutions. These products are intended to benefit individuals in the United States who are managing conditions such as diabetes, Parkinson's disease, hypertension, neuropathy, and issues with kidney function. The company's primary product line is the eBalance system, which comprises two versions: the eBalance Pro System, designed for clinical application by healthcare practitioners, and the eBalance Home System, created for personal use to promote overall well-being and alleviate pain. Both systems are operated via the eBalance Console, a central control unit that offers three distinct pre-programmed microcurrent algorithms: one for general wellness, another for pain relief, and a 'dual' mode that combines both. Additionally, these eBalance products aim to provide temporary relief for discomfort in various body parts, including the shoulders, waist, back, neck, arms, and legs. Established in 2010, the company initially operated under the name Cell MedX Corp. before officially rebranding as StimCell Energetics Inc. in November 2024. Its corporate headquarters are located in Vancouver, Canada.

Endonovo Therapeutics, Inc., a biotechnology company, specializes in the development, manufacturing, and distribution of non-invasive electroceutical medical devices designed for regenerative medicine applications. The company's primary offering is SofPulse, an advanced non-invasive therapeutic device that employs electroceutical technology. SofPulse is engineered to provide palliative relief for various conditions, including soft tissue injuries, chronic wounds, and post-operative pain and edema. Beyond these applications, Endonovo's electroceutical medical device is also utilized in treating a broad spectrum of other ailments. These include inflammation, various types of wounds, cardiovascular diseases, chronic kidney and liver disorders (such as non-alcoholic steatohepatitis), peripheral artery diseases, and ischemic stroke. Furthermore, its technology is deployed in managing central nervous system disorders like traumatic brain injury, acute concussions, post-concussion syndrome, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and maintains its headquarters in Woodland Hills, California.

Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal system and various other organs, which may stem from cancer, trauma, or congenital defects. The company's primary experimental therapy, the Cellspan Esophageal Implant, aims to treat severe esophageal disease. Beyond this, its development pipeline encompasses organ-regeneration technologies designed for the repair or replacement of damaged or diseased organs. This includes product candidates targeting diverse esophageal ailments—such as those caused by traumatic injury, caustic burns, or tissue damage from chemoradiation therapy, as well as birth defects—and solutions for colon and uterine wound reconstruction. Additionally, the company offers consumer health products, including dietary supplements, focusing on personal wellness. Founded in 2009 and headquartered in Holliston, Massachusetts, the company operated as Biostage, Inc. until its rebranding to Harvard Apparatus Regenerative Technology Inc. in July 2023.